Suono Bio is based on MIT research and is aiming to use low-frequency ultrasound to bring therapeutic compounds to target cells with greater efficiency.

Helsinn Investment Fund and Alexandria Venture Investments both invested as OncoResponse looks to advance five immuno-oncology drug candidates.

Cricket Health, developer of an integrated kidney care service that helps patients stay out of hospital, has completed an Oak HC/FT-led series A round.

BennuBio has assumed control of an existing UNM licence for cytometer technology, securing commitments from three investors to target a commercial release by next year.

University of Queensland revealed it has generated more than 100 spinouts since 1988, with probiotic drink manufacturer Perkii becoming number 100 in 2016.

Twentyeight-Seven Therapeutics has officially launched with $65m in series A funding to commercialise oncology treatments based on research at Harvard Medical School.

Novartis Venture Fund, a founding investor, co-led a $65m series A round to launch cancer treatment developer Twentyeight-Seven Therapeutics.

Guardant Health is targeting $100m in proceeds for its initial public offering on the Nasdaq Global Select Market, which would offer an exit to SoftBank.

Boston Scientific will pay $500m upfront and up to $100m in milestone payments to acquire Augmenix, providing exits to Varian Medical Systems and Ascension Health.